Immunomodulation induction phase lymphokine-activated killer activity acute phase proteins Effective treatment head neck cancer biologic response modifiers understanding vivo factors capable lymphokine-activated killer LAK cell phenomenon Eighteen patients squamous cell carcinoma head neck Killer cells patient recombinant U/ml complete medium complete medium autologous serum solution Cytotoxicity squamous cell carcinoma cell lines use standard chromium-release assays immunomodulatory capacity serum levels various acute phase proteins Autologous serum induction phase LAK phenomenon patients patients early stage II disease significant inhibition induction direct correlation inhibition acute phase protein levels inverse relationship component complement induction inhibition findings advances vivo immunomodulatory therapy elucidation mechanisms serologic inhibition induction phase LAK phenomenon Such studies modification treatment efficacy biologic response modifiers 